Last updated: February 21, 2026
What is the drug identified by NDC: 43547-0639?
This National Drug Code (NDC) corresponds to Amikacin Sulfate Injections, typically used in the treatment of severe bacterial infections. As a brand or generic, the specific formulation details, manufacturer, and approval status influence market dynamics and pricing.
How is the market structured for Amikacin Sulfate Injections?
Market segments
- Hospital Formulation: The primary market, supplied via hospital pharmacies, predominantly used for inpatient care.
- Outpatient Care: Limited, depending on local regulations and formulary inclusion.
- Generics vs. Brands: Amikacin is available as a generic, competing with brand-name products like Amikin (Eisai).
Market size estimates
- The global antibiotic injectable market was valued at approximately $11.2 billion in 2022, with aminoglycosides (including amikacin) contributing a small but stable segment.
- U.S. prescription volume in 2021 was approximately 2 million doses, with annual growth around 2-3%, driven by hospital infection control needs.
Competitive landscape
- Dominated by generic manufacturers including Hikma, Sagent, and Fresenius.
- Limited brand-name presence; Amikin remains the primary branded product but accounts for less than 10% of sales.
- Entry barriers exist due to manufacturing complexity, regulatory requirements, and hospital procurement contracts.
Regulatory status and patent considerations
- The drug is FDA-approved; the last approval date was in 1990.
- No active patents for the generic formulation after patent expiry; patent protections largely relate to manufacturing processes or other formulation patents, which are not typically relevant for generics.
- Biosimilar or alternative products have not significantly entered the market.
Price trends and projections
Current pricing landscape
| Product Type |
Price per Dosing Unit |
Key Market Factors |
| Generic Amikacin |
~$3.00 - $5.00 |
Widely available, competitive pricing |
| Brand (Amikin) |
~$15.00 - $20.00 |
Higher cost, limited supply |
Historical price trends
- Prices remained steady from 2015 through 2019.
- Slight reductions observed in 2020-2021 due to increased generic competition.
- Recent supplier consolidation has stabilized prices at a lower range.
Short-term projections (2023-2025)
- Prices are expected to remain stable barring major supply chain disruptions.
- Slight decreases are achievable as new generic manufacturers enter or expand capacity.
- Market volume growth will likely follow hospital procurement trends, projected at a compound annual growth rate (CAGR) of ~2%.
Long-term outlook (2026 and beyond)
- Price erosion may continue with increased competition.
- Emerging regional markets could see higher prices due to limited local manufacturing.
- Regulatory shifts towards cost containment and hospital formulary restrictions may pressure prices downward.
Key drivers influencing prices
- Manufacturing costs: High due to complex synthesis and sterilization processes.
- Supply chain stability: Disruptions could cause price spikes.
- Regulatory environment: Approvals for biosimilars or alternative aminoglycosides could impact market share.
- Healthcare policies: Price controls and hospital procurement strategies influence market prices.
Summary of projections
| Period |
Expected Price Range |
Assumptions |
| 2023 |
$3.00 - $5.00 |
Stable supply, unchanged competition |
| 2024 |
$2.75 - $4.75 |
Slight price declines as new entrants increase competition |
| 2025 |
$2.75 - $4.50 |
Market stabilization, possible further competition |
Key Takeaways
- The market for NDC 43547-0639 (Amikacin Sulfate) remains concentrated among generic manufacturers.
- Prices have shown limited volatility with minor declines over recent years.
- Demand is driven mainly by hospital inpatient use, with growth linked to infection control protocols.
- Future price declines depend on increased manufacturing competition and regulatory developments.
- The market is not prone to sudden price surges absent supply disruptions or regulatory changes.
FAQs
Q1: What factors could cause a sudden price increase for this drug?
A1: Supply chain disruptions, manufacturing issues, or regulatory restrictions can reduce supply and raise prices temporarily.
Q2: How do biosimilars influence aminoglycoside markets?
A2: There are currently no biosimilars for aminoglycosides like amikacin, so the impact remains limited.
Q3: Are there regional differences in pricing?
A3: Yes, pricing varies significantly globally due to local manufacturing capabilities, regulations, and competitive landscapes.
Q4: What are the key barriers for new entrants into this market?
A4: Complex manufacturing processes, regulatory approvals, and hospital procurement contracts.
Q5: How might hospital procurement policies impact prices?
A5: Contract negotiations and formulary decisions can drive prices down as hospitals favor cost-effective options.
References
[1] IQVIA. (2022). Global prescription market analysis.
[2] FDA. (2022). Approved drug products with therapeutic equivalence evaluations.
[3] MarketResearch.com. (2023). Antibiotic injectable market report.
